Newsfeeds - Spark Newswire

3 minute read

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

May 16, 9:38 AM

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

ATNX

10 minute read

Earnings Scheduled For May 16, 2022

By Benzinga Insights

May 16, 5:18 AM

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

ACRX

1 minute read

Earnings

Earnings Preview For Syros Pharmaceuticals

By Benzinga Insights

May 13, 11:05 AM

Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Syros Pharmaceuticals will report an earnings per share (EPS) of $-0.47.

SYRS

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

April 28, 3:31 PM

During Thursday, 849 stocks hit new 52-week lows.

AADI

4 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

April 26, 4:58 AM

Gainers

AGE

4 minute read

55 Biggest Movers From Friday

By Lisa Levin

April 25, 4:23 AM

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.

ALVR

1 minute read

Syros’ CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

By Vandana Singh

April 11, 9:21 AM

Syros Pharmaceuticals Inc (NASDAQ: SYRS)

AZN

2 minute read

Earnings

Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

By Benzinga Insights

March 16, 11:05 AM

According to Benzinga Pro data, during Q4, Syros Pharmaceuticals (NASDAQ:SYRS) posted sales of $7.80 million. Earnings were up 8.51%, but Syros Pharmaceuticals still reported an overall loss of $23.81 million.

SYRS

1 minute read

Syros Pharmaceuticals Q4 EPS $(0.38) Beats $(0.47) Estimate, Sales $7.80M Beat $4.80M Estimate

By Bill Haddad

March 15, 7:33 AM

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.47) by 19.15 percent. This is a 38.71 percent increase over losses of $(0.62) per share

SYRS

4 minute read

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

By Shanthi Rexaline

March 13, 5:37 PM

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

ACIU